These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 38270219)

  • 1. Belantamab mafodotin, lenalidomide, and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: Analysis of belantamab mafodotin-associated ocular adverse events and their impact on daily functioning from the part 1 of a phase 1/2 study.
    Gavriatopoulou M; Ntanasis-Stathopoulos I; Malandrakis P; Fotiou D; Migkou M; Theodorakakou F; Spiliopoulou V; Kanellias N; Eleutherakis-Papaiakovou E; Roussou M; Psarros G; Kastritis E; Dimopoulos MA; Terpos E
    Am J Hematol; 2024 Mar; 99(3):502-504. PubMed ID: 38270219
    [No Abstract]   [Full Text] [Related]  

  • 2. Belantamab mafodotin, lenalidomide and dexamethasone in transplant-ineligible patients with newly diagnosed multiple myeloma: part 1 results of a phase I/II study.
    Terpos E; Gavriatopoulou M; Ntanasis-Stathopoulos I; Malandrakis P; Fotiou D; Migkou M; Theodorakakou F; Spiliopoulou V; Kostopoulos IV; Syrigou RE; Eleutherakis-Papaiakovou E; Gkolfinopoulos S; Tsitsilonis OE; Kastritis E; Dimopoulos MA
    Haematologica; 2024 Aug; 109(8):2594-2605. PubMed ID: 38356458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Belantamab Mafodotin, Pomalidomide, and Dexamethasone in Multiple Myeloma.
    Dimopoulos MA; Beksac M; Pour L; Delimpasi S; Vorobyev V; Quach H; Spicka I; Radocha J; Robak P; Kim K; Cavo M; Suzuki K; Morris K; Pompilus F; Phillips-Jones A; Zhou XL; Fulci G; Sule N; Kremer BE; Opalinska J; Mateos MV; Trudel S;
    N Engl J Med; 2024 Aug; 391(5):408-421. PubMed ID: 38828951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): a phase 3, open-label, randomised study.
    Dimopoulos MA; Hungria VTM; Radinoff A; Delimpasi S; Mikala G; Masszi T; Li J; Capra M; Maiolino A; Pappa V; Chraniuk D; Osipov I; Leleu X; Low M; Matsumoto M; Sule N; Li M; McKeown A; He W; Bright S; Currie B; Perera S; Boyle J; Roy-Ghanta S; Opalinska J; Weisel K
    Lancet Haematol; 2023 Oct; 10(10):e801-e812. PubMed ID: 37793771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Belantamab mafodotin, pomalidomide and dexamethasone in refractory multiple myeloma: a phase 1/2 trial.
    Trudel S; McCurdy A; Louzada ML; Parkin S; White D; Chu MP; Kotb R; Mian H; Othman I; Su J; Khan A; Gul E; Reece D
    Nat Med; 2024 Feb; 30(2):543-551. PubMed ID: 38177852
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pembrolizumab plus lenalidomide and dexamethasone for patients with treatment-naive multiple myeloma (KEYNOTE-185): a randomised, open-label, phase 3 trial.
    Usmani SZ; Schjesvold F; Oriol A; Karlin L; Cavo M; Rifkin RM; Yimer HA; LeBlanc R; Takezako N; McCroskey RD; Lim ABM; Suzuki K; Kosugi H; Grigoriadis G; Avivi I; Facon T; Jagannath S; Lonial S; Ghori RU; Farooqui MZH; Marinello P; San-Miguel J;
    Lancet Haematol; 2019 Sep; 6(9):e448-e458. PubMed ID: 31327689
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pembrolizumab, lenalidomide and dexamethasone post autologous transplant in patients with high-risk multiple myeloma.
    Biran N; Gourna Paleoudis E; Feinman R; Vesole DH; Zenreich J; Wang S; Ahn J; Bansal M; Rowley S; Donato M; Pecora AL; Richter J; Anand P; McBride L; Ivanovski K; Korngold R; Siegel DS
    Am J Hematol; 2021 Nov; 96(11):E430-E433. PubMed ID: 34435374
    [No Abstract]   [Full Text] [Related]  

  • 8. Elotuzumab, lenalidomide, bortezomib, dexamethasone, and autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GMMG-HD6): results from a randomised, phase 3 trial.
    Mai EK; Goldschmid H; Miah K; Bertsch U; Besemer B; Hänel M; Krzykalla J; Fenk R; Schlenzka J; Munder M; Dürig J; Blau IW; Huhn S; Hose D; Jauch A; Kunz C; Mann C; Weinhold N; Scheid C; Schroers R; von Metzler I; Schieferdecker A; Thomalla J; Reimer P; Mahlberg R; Graeven U; Kremers S; Martens UM; Kunz C; Hensel M; Benner A; Seidel-Glätzer A; Weisel KC; Raab MS; Salwender HJ;
    Lancet Haematol; 2024 Feb; 11(2):e101-e113. PubMed ID: 38302221
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Belantamab Mafodotin for the Treatment of Multiple Myeloma: An Overview of the Clinical Efficacy and Safety.
    Offidani M; Corvatta L; Morè S; Olivieri A
    Drug Des Devel Ther; 2021; 15():2401-2415. PubMed ID: 34103900
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Belantamab mafodotin for relapsed or refractory multiple myeloma.
    Gil-Sierra MD; Briceño-Casado MDP
    J Oncol Pharm Pract; 2022 Sep; 28(6):1375-1380. PubMed ID: 35306910
    [No Abstract]   [Full Text] [Related]  

  • 11. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study.
    Lonial S; Lee HC; Badros A; Trudel S; Nooka AK; Chari A; Abdallah AO; Callander N; Lendvai N; Sborov D; Suvannasankha A; Weisel K; Karlin L; Libby E; Arnulf B; Facon T; Hulin C; Kortüm KM; Rodríguez-Otero P; Usmani SZ; Hari P; Baz R; Quach H; Moreau P; Voorhees PM; Gupta I; Hoos A; Zhi E; Baron J; Piontek T; Lewis E; Jewell RC; Dettman EJ; Popat R; Esposti SD; Opalinska J; Richardson P; Cohen AD
    Lancet Oncol; 2020 Feb; 21(2):207-221. PubMed ID: 31859245
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addition of elotuzumab to lenalidomide and dexamethasone for patients with newly diagnosed, transplantation ineligible multiple myeloma (ELOQUENT-1): an open-label, multicentre, randomised, phase 3 trial.
    Dimopoulos MA; Richardson PG; Bahlis NJ; Grosicki S; Cavo M; Beksaç M; Legieć W; Liberati AM; Goldschmidt H; Belch A; Magen H; Larocca A; Laubach JP; Petrucci MT; Reece D; White D; Mateos MV; Špička I; Lazaroiu M; Berdeja J; Kaufman JL; Jou YM; Ganetsky A; Popa McKiver M; Lonial S; Weisel K;
    Lancet Haematol; 2022 Jun; 9(6):e403-e414. PubMed ID: 35550060
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Elotuzumab plus lenalidomide and dexamethasone for newly diagnosed multiple myeloma: a randomized, open-label, phase 2 study in Japan.
    Kubo K; Hori M; Ohta K; Handa H; Hatake K; Matsumoto M; Hagiwara S; Ohashi K; Nakaseko C; Suzuki K; Ito S; Kinoshita G; Shelat SG; Miyoshi M; Takezako N
    Int J Hematol; 2020 Jan; 111(1):65-74. PubMed ID: 31701481
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EMA Review of Belantamab Mafodotin (Blenrep) for the Treatment of Adult Patients with Relapsed/Refractory Multiple Myeloma.
    Tzogani K; Penttilä K; Lähteenvuo J; Lapveteläinen T; Lopez Anglada L; Prieto C; Garcia-Ochoa B; Enzmann H; Gisselbrecht C; Delgado J; Pignatti F
    Oncologist; 2021 Jan; 26(1):70-76. PubMed ID: 33179377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Continuous lenalidomide and low-dose dexamethasone in patients with transplant-ineligible newly diagnosed MM: FIRST trial subanalysis of Canadian/US patients.
    Belch A; Bahlis N; White D; Cheung M; Chen C; Shustik C; Song K; Tosikyan A; Dispenzieri A; Anderson K; Brown D; Robinson S; Srinivasan S; Facon T
    Cancer Med; 2020 Dec; 9(23):8923-8930. PubMed ID: 33049118
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sequential therapy of four cycles of bortezomib, melphalan, and prednisolone followed by continuous lenalidomide and dexamethasone for transplant-ineligible newly diagnosed multiple myeloma.
    Isa R; Uoshima N; Takahashi R; Nakano-Akamatsu S; Kawata E; Kaneko H; Shimura K; Kamitsuji Y; Takimoto-Shimomura T; Mizutani S; Chinen Y; Ohshiro M; Fujino T; Kawaji Y; Uchiyama H; Sasaki N; Tsukamoto T; Shimura Y; Kobayashi T; Taniwaki M; Kuroda J;
    Ann Hematol; 2020 Jan; 99(1):137-145. PubMed ID: 31768675
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment with low-dose, single-agent belantamab mafodotin is safe and provides long-term responses in heavily pretreated multiple myeloma patients.
    Avivi I; Shragai T; Luttwak E; Trestman S; Cohen YC
    Eur J Haematol; 2024 Mar; 112(3):367-370. PubMed ID: 37882735
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial.
    Perrot A; Facon T; Plesner T; Usmani SZ; Kumar S; Bahlis NJ; Hulin C; Orlowski RZ; Nahi H; Mollee P; Ramasamy K; Roussel M; Jaccard A; Delforge M; Karlin L; Arnulf B; Chari A; He J; Ho KF; Van Rampelbergh R; Uhlar CM; Wang J; Kobos R; Gries KS; Fastenau J; Weisel K
    J Clin Oncol; 2021 Jan; 39(3):227-237. PubMed ID: 33326255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Belantamab Mafodotin Revival in Multiple Myeloma Therapy.
    Trudel S; Stewart AK
    N Engl J Med; 2024 Aug; 391(5):461-462. PubMed ID: 39083777
    [No Abstract]   [Full Text] [Related]  

  • 20. Isatuximab, carfilzomib, lenalidomide, and dexamethasone in patients with newly diagnosed, transplantation-eligible multiple myeloma (SKylaRk): a single-arm, phase 2 trial.
    O'Donnell E; Mo C; Yee AJ; Nadeem O; Laubach J; Rosenblatt J; Munshi N; Midha S; Cirstea D; Chrysafi P; Horick N; Richardson PG; Raje N
    Lancet Haematol; 2024 Jun; 11(6):e415-e424. PubMed ID: 38677302
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.